SCHEMBL699296

SCHEMBL699296

CCOC(=O)[C@@H]1C[C@@H](Sc2ccccc2C(F)(F)F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSS P25774 2/20 0.38
NR1D1 P20393 2/20 0.36
SCD O00767 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALOX5 P09917 1/20 0.35
RBP4 P02753 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
TACR1 P25103 3/20 0.34
CACNA1F O60840 1/20 0.34
CACNA1D Q01668 1/20 0.34
CACNA1S Q13698 1/20 0.34
CACNA1C Q13936 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724889 0.89 NR1H2 (0.40) KDM4ESCDRBP4CYP1A2POLB
SCHEMBL12589813 0.83 KMT2A (0.44) ALDH1A1MEN1KMT2ACTSSCYP1A2
SCHEMBL2059320 0.83 KMT2A (0.44) ALDH1A1MEN1KMT2ACTSSCYP1A2
SCHEMBL702381 0.80 CTSS (0.45) KDM4EALDH1A1CTSS
SCHEMBL3196097 0.78 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ACTSSCYP1A2
SCHEMBL6947045 0.78 KMT2A (0.41) KDM4EALDH1A1MEN1KMT2ANR1D1
SCHEMBL6947047 0.78 KMT2A (0.41) KDM4EALDH1A1MEN1KMT2ANR1D1
SCHEMBL716249 0.77 CCNT1 (0.40) CTSSCYP1A2POLBCYP3A4CYP2C19
SCHEMBL28721184 0.76 HTRA1 (0.54) ALDH1A1MEN1KMT2ACYP1A2POLB
SCHEMBL2685355 0.75 NR1H2 (0.42) ALDH1A1CTSSCYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 KDM4E 2752/4885ALDH1A1 727/4885MEN1 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.